The effect of adjuvant chemotherapy in patients with intrahepatic cholangiocarcinoma: a matched pair analysis

被引:32
|
作者
Schweitzer, Nora [1 ]
Weber, Tim [1 ]
Kirstein, Martha M. [1 ]
Fischer, Mareike [1 ,2 ]
Kratzel, Anna-Maria [1 ]
Reineke-Plaass, Tanja [3 ]
Lehner, Frank [4 ]
Manns, Michael P. [1 ]
Vogel, Arndt [1 ]
机构
[1] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Carl Neuberg Str 1, D-30625 Hannover, Germany
[2] Klinikum Hildesheim, Dept Cardiol Angiol & Intens Care, Senator Braun Allee 33, D-31135 Hildesheim, Germany
[3] Hannover Med Sch, Dept Pathol, Carl Neuberg Str 1, D-30625 Hannover, Germany
[4] Hannover Med Sch, Dept Gen Visceral & Transplantat Surg, Carl Neuberg Str 1, D-30625 Hannover, Germany
关键词
Cholangiocarcinoma; CCA; Intrahepatic; ICC; Survival; Adjuvant chemotherapy; PROGNOSTIC-FACTORS; SURGICAL-TREATMENT; MORTALITY-RATES; UNITED-STATES; TRENDS; SURVIVAL; BILIARY; EXPERIENCE; INCREASE; CANCER;
D O I
10.1007/s00432-017-2392-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of this study was to identify prognostic factors of patients with intrahepatic cholangiocarcinoma (ICC) treated with resection and to investigate the effect of adjuvant chemotherapy (CT). Patients with ICC diagnosed between 2000 and 2015 treated at Hannover Medical School were included. Clinicopathologic characteristics were analyzed in univariate and multivariate analysis. In a matched pair survival analysis, patients with or without adjuvant CT were matched by these prognostic factors. Two hundred and ten patients were included. Median survival was 28.7 months, 1-, 3-, and 5-year survival rates were 72.8%, 29.6%, and 14.1%, respectively. In multivariate analysis, lymph node involvement (p = 0.006, HR 1.84), larger tumor size (p = 0.013, HR 1.79), vascular invasion (p = 0.038, HR 1.70), and prolongation of prothrombin time (p < 0.001, HR 4.20) were significantly related to poor survival. Thirty-nine patients received adjuvant CT of which 60% had lymph node involvement. Each 25 patients with and without adjuvant CT were matched to the identified prognostic factors. The median survival of patients with adjuvant CT was 33.5 months, compared to 18 months in the control group (p = 0.002). The 1-, 3-, and 5-year survival rates were 96, 36, and 12%, compared to 60, 4, and 0% in non-treated patients. We identified several prognostic factors for patients with ICC treated with resection. Our data support the use of adjuvant CT in patients with ICC. The results of prospective randomized controlled studies will clarify the role of adjuvant CT in the future.
引用
收藏
页码:1347 / 1355
页数:9
相关论文
共 50 条
  • [1] The effect of adjuvant chemotherapy in patients with intrahepatic cholangiocarcinoma: a matched pair analysis
    Nora Schweitzer
    Tim Weber
    Martha M. Kirstein
    Mareike Fischer
    Anna-Maria Kratzel
    Tanja Reineke-Plaaß
    Frank Lehner
    Michael P. Manns
    Arndt Vogel
    Journal of Cancer Research and Clinical Oncology, 2017, 143 : 1347 - 1355
  • [2] Adjuvant chemotherapy for intrahepatic cholangiocarcinoma: approaching clinical practice consensus?
    Altman, Ariella M.
    Kizy, Scott
    Marmor, Schelomo
    Hui, Jane Y. C.
    Tuttle, Todd M.
    Jensen, Eric H.
    Denbo, Jason W.
    HEPATOBILIARY SURGERY AND NUTRITION, 2020, 9 (05) : 577 - +
  • [3] Adjuvant chemotherapy improves oncological outcomes of resectable intrahepatic cholangiocarcinoma A meta-analysis
    Ma, Ka Wing
    Cheung, Tan To
    Leung, Brian
    She, Brian Wong Hoi
    Chok, Kenneth Siu Ho
    Chan, Albert Chi Yan
    Dai, Wing Chiu
    Lo, Chung Mau
    MEDICINE, 2019, 98 (05)
  • [4] The effect of adjuvant chemotherapy in resectable cholangiocarcinoma: A meta-analysis and systematic review
    Wang, Ming-Liang
    Ke, Zhang-Yan
    Yin, Shuai
    Liu, Chen-Hai
    Huang, Qiang
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2019, 18 (02) : 110 - 116
  • [5] A Nomogram Model to Predict Early Recurrence of Patients With Intrahepatic Cholangiocarcinoma for Adjuvant Chemotherapy Guidance: A Multi-Institutional Analysis
    Li, Qi
    Zhang, Jian
    Chen, Chen
    Song, Tianqiang
    Qiu, Yinghe
    Mao, Xianhai
    Wu, Hong
    He, Yu
    Cheng, Zhangjun
    Zhai, Wenlong
    Li, Jingdong
    Zhang, Dong
    Geng, Zhimin
    Tang, Zhaohui
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [6] Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis
    Yadav, Siddhartha
    Xie, Hao
    Bin-Riaz, Irbaz
    Sharma, Prabin
    Durani, Urshila
    Goyal, Gaurav
    Borah, Bijan
    Borad, Mitesh J.
    Smoot, Rory L.
    Roberts, Lewis R.
    Go, Ronald S.
    McWilliams, Robert R.
    Mahipal, Amit
    EJSO, 2019, 45 (08): : 1432 - 1438
  • [7] Prognosis of the intrahepatic cholangiocarcinoma after resection: hepatitis B virus infection and adjuvant chemotherapy are favorable prognosis factors
    Liu, Rui-qing
    Shen, Shu-jing
    Hu, Xiu-feng
    Liu, Jie
    Chen, Li-juan
    Li, Xing-ya
    CANCER CELL INTERNATIONAL, 2013, 13
  • [8] Evaluation of Postoperative Adjuvant Chemotherapy for Intrahepatic Cholangiocarcinoma Patients undergoing R1 and R2 Resections
    Bhudhisawasdi, Vajarabhongsa
    Talabnin, Chutima
    Pugkhem, Ake
    Khuntikeo, Narong
    Seow, O-Tur
    Chur-in, Siri
    Pairojkul, Chawalit
    Wongkham, Sopit
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 : 169 - 174
  • [9] Impact of adjuvant chemotherapy on survival in patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis
    Reames, Bradley N.
    Bagante, Fabio
    Ejaz, Aslam
    Spolverato, Gaya
    Ruzzenente, Andrea
    Weiss, Matthew
    Alexandrescu, Sorin
    Marques, Hugo P.
    Aldrighetti, Luca
    Maithel, Shishir K.
    Pulitano, Carlo
    Bauer, Todd W.
    Shen, Feng
    Poultsides, George A.
    Soubrane, Oliver
    Martel, Guillaume
    Koerkamp, Bas G.
    Guglielmi, Alfredo
    Itaru, Endo
    Pawlik, Timothy M.
    HPB, 2017, 19 (10) : 901 - 909
  • [10] Predictive risk-score model to select patients with intrahepatic cholangiocarcinoma for adjuvant chemotherapy
    Endo, Yutaka
    Moazzam, Zorays
    Alaimo, Laura
    Lima, Henrique A.
    Munir, Muhammad M.
    Shaikh, Chanza F.
    Guglielmi, Alfredo
    Aldrighetti, Luca
    Weiss, Matthew
    Bauer, Todd W.
    Alexandrescu, Sorin
    Poultsides, George A.
    Kitago, Minoru
    Maithel, Shishir K.
    Marques, Hugo P.
    Martel, Guillaume
    Pulitano, Carlo
    Shen, Feng
    Cauchy, Francois
    Koerkamp, Bas G.
    Endo, Itaru
    Pawlik, Timothy M.
    HPB, 2023, 25 (02) : 229 - 238